Strategic Legal Counsel for the Life Sciences Industry
Bringing scientific innovation to market requires more than a breakthrough idea. It requires strategic legal counsel that understands the science, regulatory environment, and business realities of developing and commercializing innovative products.
Frier Levitt is a national boutique law firm serving dynamic clients across the healthcare, life sciences, and pharmacy industries. Our multidisciplinary Life Sciences team advises clients on FDA regulatory law, healthcare compliance, corporate transactions, government investigations, and complex litigation.
Our team includes scientifically trained regulatory counsel, pharmacist-attorneys, transactional attorneys, litigators, and former federal prosecutors. Together we provide life sciences companies, investors and innovators with practical guidance throughout the business and product lifecycle.
Life Sciences Industry Experience
Frier Levitt advises emerging and established life sciences companies on the legal, regulatory, and business issues affecting product development, market entry, commercialization, and growth.
Our attorneys counsel clients navigating requirements and enforcement priorities involving the U.S. Food and Drug Administration (FDA), Drug Enforcement Administration (DEA), Federal Trade Commission (FTC), U.S. Department of Agriculture (USDA), and other federal and state regulatory authorities. We help clients assess regulatory risk, structure compliant business arrangements, protect intellectual property, negotiate critical commercial relationships, pursue strategic transactions, and respond to investigations and disputes.
Our multidisciplinary approach brings together regulatory, compliance, transactional, and litigation experience to address interconnected legal and business issues as companies develop, commercialize, and grow.
Our FDA regulatory attorneys advise clients across the full product lifecycle, from research and development and regulatory strategy through manufacturing, marketing, distribution, and post-market compliance.
We counsel domestic and international companies operating across pharmaceuticals, biologics, medical devices, food and beverage, dietary supplements, cosmetics, cannabis, hemp, psychedelics, and other FDA-regulated products.
Our work includes regulatory strategy and compliance, product classification, labeling and promotional review, manufacturing and supply chain issues, inspections, warning letters, enforcement matters, and regulatory considerations arising in corporate transactions and due diligence.
Frier Levitt represents life sciences companies, investors, founders, and strategic partners in mergers and acquisitions, private equity and venture capital transactions, joint ventures, strategic affiliations, licensing arrangements, and other commercial transactions.
Our industry knowledge helps clients identify regulatory and operational risks throughout the transaction lifecycle, from early-stage investment and due diligence through acquisitions, strategic partnerships, commercial expansion, and exit transactions.
Frier Levitt represents life sciences companies in government investigations, regulatory enforcement actions, commercial disputes, and complex litigation.
Our regulatory attorneys, former federal prosecutors, and litigators handle matters involving federal and state regulators, contractual disputes, false advertising and unfair competition, fraud and abuse, product-related issues, and other disputes affecting life sciences businesses.
Who We Represent
Frier Levitt works with companies, investors and other stakeholders throughout the life sciences ecosystem, including:
- Pharmaceutical and biotechnology companies
- Medical device companies
- Digital health and technology companies
- Peptide and GLP-1 companies
- Food and dietary supplements companies
- Cosmetics companies
- Startups and Emerging life sciences companies
- Contract Development and Manufacturing Organizations
- Wholesalers and distributors
- Clinical Research Organizations and research institutions
- Cannabis, hemp, and psychedelics businesses
- Private equity and venture capital investors
Latest Insights
Stay informed. Read our latest Life Science updates and articles.